Invivyd, Inc. (IVVD) Stock Price & Analysis
Invivyd, Inc. (IVVD) closed at USD 0.67 on Thursday, October 15, 2026, up 10.04% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.61; the Oct 15, 2026 session ranged USD 0.61–0.68 on volume of 3,265,513 shares. Market capitalization is $197.13M, with a 52-week range of USD 0.53–3.07 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IVVD.md
Key facts (IVVD)
- 1 of 80 tracked superinvestors hold IVVD (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 10 (range 10–10).
- Total return with dividends: 1Y -61.8% vs S&P 500 +18.1%; 5Y -97.9% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.15, revenue estimate $15.0M.
Superinvestors (SEC 13F-HR, Q2 2026) (IVVD)
1 of 80 tracked investors hold IVVD. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 0.15% | $16.6M | Unchanged |
Analysts (IVVD)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 10 (low 10, high 10).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-14 | BTIG | Reiterated | Buy | $10 |
| 2026-08-27 | Cantor Fitzgerald | Reiterated | Overweight | $10 |
| 2026-07-07 | BTIG | Reiterated | Buy | $10 |
Total return (dividends reinvested) (IVVD)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -61.8% | -97.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -61.9% | -53.9% |
| Volatility (annualized) | 107.8% | 146.4% |
| Max drawdown | -81.4% (Dec 2025→Jul 2026) | -99.2% (Nov 2021→Jan 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 0.67 |
|---|---|
| Change | ▲ 10.04% (up) |
| Previous Close | USD 0.61 |
| Open | USD 0.62 |
| Day Range | USD 0.61 – 0.68 |
| 52-Week Range | USD 0.53 – 3.07 |
| Volume | 3,265,513 shares |
| Market Cap | $197.13M |
| Exchange | NGM |
Technical Analysis (IVVD)
Nexqual's technical model rates IVVD "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.95 (neutral) |
| vs SMA50 | Below (USD 0.82) |
| MACD | -0.05 (negative) |
Analyst Ratings (IVVD)
Wall Street analysts rate IVVD "Buy" based on 3 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (IVVD)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $15.04M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.14 vs est -0.14 ▲ beat |
| 2026-03-31 | USD -0.13 vs est -0.08 ▼ miss |
| 2025-09-30 | USD -0.06 vs est -0.1 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (IVVD)
| Total Revenue | $58.37M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +21.20% |
| Gross Margin | +92.23% |
| Operating Margin | -320.76% |
| Profit Margin | -183.90% |
| ROE | -95.89% |
| Debt / Equity | 0.05 |
| Current Ratio | 5.87 |
| Total Cash | $160.08M |
| Total Debt | $8.39M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$58.29M (-109.1% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (IVVD)
Nexqual rates Invivyd, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +110% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $160M cash vs $8M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$58M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -96%, ROA -45.7% |
Ownership (IVVD)
| Insider Ownership | +7.16% |
|---|---|
| Institutional Ownership | +86.93% |
| Shares Outstanding | 294.76M |
| Float | 207.83M |
| Short % of Float | +12.69% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (IVVD)
Invivyd, Inc. is led by Marc William Elia (age 49), CEO & Chairperson of the Board, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Chairperson of the Board | Marc William Elia (age 49) |
|---|---|
| CFO and Principal Financial & Accounting Officer | William E. Duke Jr. (age 53) |
| Chief Scientific Officer | Robert D. Allen (age 55) |
| Senior Vice President of Regulatory Affairs | Rachael Gerlach |
| Senior Vice President of Finance | Katie Falzone |
Major Backers & Investors (IVVD)
Notable institutional backers of Invivyd, Inc. include Jupiter Topco LLC, BVF Inc., Maverick Capital Ltd., according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 11.59% |
| BVF Inc. | 9.56% |
| Maverick Capital Ltd. | 6.44% |
| Perceptive Advisors Llc | 6.27% |
| M28 Capital Management LP | 3.14% |
| Saturn V Capital Management LP | 2.85% |
| Soleus Capital Management, L.P. | 2.62% |
| Point72 Asset Management, L.P. | 2.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.39% |
| Vanguard Group | 7.01% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt